1. Obesity contributes to telomere shortening in polycystic ovary syndrome.
- Author
-
Kogure GS, Verruma CG, Santana BA, Calado RT, Ferriani RA, Furtado CLM, and Dos Reis RM
- Subjects
- Humans, Female, Adult, Young Adult, Insulin Resistance, Telomere metabolism, Leukocytes metabolism, Biomarkers blood, Polycystic Ovary Syndrome genetics, Polycystic Ovary Syndrome blood, Polycystic Ovary Syndrome metabolism, Obesity genetics, Obesity blood, Telomere Shortening, Body Mass Index
- Abstract
Polycystic ovary syndrome (PCOS) is a multifactorial disorder and obesity occurs in 38% to 88% of these women. Although hyperandrogenism may contribute to telomere lengthening, increased body mass index (BMI) is associated with telomere erosion. We sought to compare leukocyte telomere length (LTL) in PCOS women with normal, overweight, and obese BMI. We evaluated the relationship between LTL and clinical variables of PCOS and inflammatory biomarkers independent of BMI. A total of 348 women (243 PCOS and 105 non-PCOS) were evaluated for anthropometric measures, total testosterone, androstenedione, estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex hormone-binding globulin (SHBG), free androgen index (FAI), fasting insulin and glycemia, lipid profile, homocysteine, C-reactive protein (CRP) and homeostatic model of insulin resistance (HOMA-IR). LTL was measured by qPCR. The PCOS group presented higher weight, waist circumference, BMI, testosterone, LH, fasting insulin, FAI, and HOMA-IR, and lower E2, SHBG, and fasting glycemia measures compared with the non-PCOS. When stratified by BMI, LTL was increased in all subgroups in PCOS compared to non-PCOS. However, in the PCOS group, LTL was lower in overweight (P = 0.0187) and obese (P = 0.0018) compared to normal-weight women. The generalized linear model showed that BMI, androstenedione, homocysteine, and CRP were associated with telomere biology. Women with PCOS had longer LTL, however, overweight or obesity progressively contributes to telomere shortening and may affect reproductive outcomes of PCOS, while androstenedione may increase LTL., (© 2024. The Author(s), under exclusive licence to Society for Reproductive Investigation.)
- Published
- 2024
- Full Text
- View/download PDF